Compare RH & VERA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | RH | VERA |
|---|---|---|
| Founded | 1979 | 2016 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Other Specialty Stores | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 2.8B | 3.2B |
| IPO Year | 2011 | 2021 |
| Metric | RH | VERA |
|---|---|---|
| Price | $127.55 | $43.53 |
| Analyst Decision | Hold | Strong Buy |
| Analyst Count | 15 | 10 |
| Target Price | ★ $172.93 | $81.30 |
| AVG Volume (30 Days) | ★ 1.6M | 1.1M |
| Earning Date | 03-31-2026 | 05-05-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 74.31 | N/A |
| EPS | ★ 6.31 | N/A |
| Revenue | ★ $1,193,046,000.00 | N/A |
| Revenue This Year | $9.90 | N/A |
| Revenue Next Year | $8.57 | $472.48 |
| P/E Ratio | $19.87 | ★ N/A |
| Revenue Growth | ★ 24.52 | N/A |
| 52 Week Low | $106.30 | $18.76 |
| 52 Week High | $256.78 | $56.05 |
| Indicator | RH | VERA |
|---|---|---|
| Relative Strength Index (RSI) | 44.07 | 58.90 |
| Support Level | $127.00 | $37.54 |
| Resistance Level | $142.48 | $56.05 |
| Average True Range (ATR) | 6.66 | 2.25 |
| MACD | 2.20 | 0.55 |
| Stochastic Oscillator | 59.39 | 61.37 |
RH is a luxury furniture and lifestyle retailer primarily operating in the $136 billion domestic furniture and home furnishing industry. The firm offers merchandise across many categories, including furniture, lighting, textiles, bath, decor, and is growing the presence of its hospitality business with 24 restaurant locations, including RH Guesthouse. RH innovates, curates, and integrates products, categories, services, and businesses across channels and brand extensions (RH Modern and Waterworks, for example). RH is fully integrated across channels and is positioned to broaden its addressable market over the next decade via expanding abroad, its World of RH digital platform (highlighting offerings outside of home furnishings), and offerings in architecture, media, and more.
Vera Therapeutics Inc is a clinical stage biotechnology company. It is focused on developing and commercializing transformative treatments for patients with serious immunological diseases. The company's product candidate is atacicept, a fusion protein self-administered as a subcutaneous injection once weekly that blocks both B lymphocyte stimulator and a proliferation-inducing ligand, which stimulate B cells and plasma cells to produce autoantibodies contributing to certain autoimmune diseases.